The role of using circulating tumor dna in the treatment of disseminated patients with non-small cell lung cancer



This article provides explanations and prerequisites for the use of circulating tumor DNA (ctDNA) in the diagnosis and treatment of non-small cell lung cancer (NSCLC). The paper presents the results of large studies showing the possibility of determining TMB (tumor mutation burden) using ctDNA analysis, which is a promising method for determining the sensitivity of a tumor to immunotherapy with immune checkpoint inhibitors. A promising possibility of monitoring the disease during and after treatment based on the qualitative and quantitative determination of the level of ctDNA in blood plasma has been shown.